New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|March 14, 2019
Highlighting CAR T Cell Options for Relapsed/Refractory DLBCL
Author(s)David Miklos, MD
David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.
Advertisement
David Miklos, MD, associate professor of medicine at Stanford University, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma (DLBCL).
Miklos says it is important to know that chimeric antigen receptor (CAR) T cells are effective and available for patients with relapsed/refractory DLBCL.
Advertisement
Related to this article
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
5